VYNE Therapeutics Inc (VYNE)Healthcare | Biotechnology | Stewartsville, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 1:07 p.m. UTC
The immediate outlook is bearish due to a severe deterioration in business fundamentals. Revenue has contracted by nearly 58% year-over-year, while operating margins have collapsed to -44%, indicating the company is burning cash aggressively without generating sales. The balance sheet, while currently showing a massive current ratio of 20x, is propped up by non-operational factors rather than organic liquidity, and free cash flow is deeply negative. The recent news confirms this distress: the company is executing a drastic 1-for-50 reverse stock split and distributing a special dividend, which are classic signs of capital preservation efforts in a failing venture rather than value creation. While the upcoming merger with Yarrow Bioscience offers a theoretical path to survival, the current standalone entity is a value trap with no sustainable growth trajectory. The recent price action shows the stock trading below its 50-day moving average, reflecting the market's rejection of the current business model. Consequently, the short-term view remains cautious as the merger timeline introduces significant execution risk, and the long-term view is severely compromised by the lack of revenue growth and negative returns on equity. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2026-07-22 |
| Last Dividend Date | 2026-07-22 |
| Revenue per Share | 0.53 |
| Market Cap | 19,069,540 |
| Forward P/E | -0.35 |
| Beta | 2.01 |
| Website | https://vynetherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5263014 |
| Address1 | P.O. BOX 125 |
| All Time High | 143,495.98 |
| All Time Low | 14.025 |
| Ask | 31.36 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 47,289 |
| Average Volume | 17,632 |
| Average Volume10Days | 47,289 |
| Beta | 2.006 |
| Bid | 20.35 |
| Bid Size | 200 |
| Book Value | 36.934 |
| City | Stewartsville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Currency | USD |
| Current Price | 28.56 |
| Current Ratio | 20.865 |
| Date Short Interest | 1,784,073,600 |
| Day High | 28.56 |
| Day Low | 23.37 |
| Ebitda | -24,345,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.241 |
| Enterprise To Revenue | -12.945 |
| Enterprise Value | -5,876,852 |
| Ex Dividend Date | 1,784,678,400 |
| Exchange | NCM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 34.0342 |
| Fifty Two Week High | 46.95 |
| Fifty Two Week Low | 14.025 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 613,692 |
| Forward Eps | -82.5 |
| Forward P E | -0.3461818 |
| Free Cashflow | -20,400,000 |
| Full Time Employees | 10 |
| Fullday Change | 28.56 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 28.56 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 454,000 |
| Held Percent Insiders | 0.17934999 |
| Held Percent Institutions | 0.39619 |
| Implied Shares Outstanding | 667,701 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Dividend Date | 1,784,678,400 |
| Last Dividend Value | 20.121 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,785,110,400 |
| Last Split Factor | 1:50 |
| Long Business Summary | VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey. |
| Long Name | VYNE Therapeutics Inc |
| Market Cap | 19,069,540 |
| Max Age | 86,400 |
| Message Board Id | finmb_6511914 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -21,718,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Open | 25.5 |
| Operating Cashflow | -25,744,000 |
| Operating Margins | -44.37209 |
| Payout Ratio | 0.0 |
| Phone | 800 775 7936 |
| Previous Close | 0.0 |
| Price Hint | 2 |
| Price To Book | 0.77327126 |
| Price To Sales Trailing12 Months | 42.00339 |
| Profit Margins | 0.0 |
| Quick Ratio | 20.168 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 28.56 |
| Regular Market Day Low | 23.37 |
| Regular Market Open | 25.5 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 93,256 |
| Return On Assets | -0.37013 |
| Return On Equity | -0.63162 |
| Revenue Growth | -0.574 |
| Revenue Per Share | 0.53 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 667,701 |
| Shares Percent Shares Out | 0.0055 |
| Shares Short | 3,679 |
| Shares Short Previous Month Date | 1,781,481,600 |
| Shares Short Prior Month | 2,201 |
| Short Name | VYNE Therapeutics Inc. |
| Short Percent Of Float | 0.0056 |
| Short Ratio | 0.15 |
| State | NJ |
| Symbol | VYNE |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 24,928,000 |
| Total Cash Per Share | 37.37 |
| Total Debt | 0 |
| Total Revenue | 454,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -27.58 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 28.596624 |
| Underlying Symbol | VYNE |
| Uuid | 6b428866-1c06-3cdf-aea1-c192e2cb997e |
| Volume | 93,256 |
| Website | https://vynetherapeutics.com |
| Zip | 8,886 |